77
Views
3
CrossRef citations to date
0
Altmetric
Original Research

Primary site surgery for elderly patients with distant metastatic pancreatic neuroendocrine tumor: to do or not to do?

, &
Pages 1419-1432 | Published online: 06 Aug 2019

Figures & data

Figure 1 Patient screening process.

Abbreviations: pNET, pancreatic neuroendocrine tumor; SEER, Surveillance Epidemiology and End Results.
Figure 1 Patient screening process.

Table 1 Characteristics of patients older than 65 years included in the study

Table 2 Logistic regression analysis of characteristics for PSS in elderly patients (≥65 years)

Table 3 Multivariate regression analysis of characteristics for survival in elderly patients (≥65 years) before PSM

Table 4 Multivariate regression analysis of characteristics for survival in elderly patients (: Multfter PSM)

Figure 2 Overall survival and cancer-specific survival in elderly patients (≥65 years) with metastatic pNET who underwent primary site surgery (PSS) and no primary site surgery (NPSS), before and after propensity score matching (PSM).

Notes: (A) Kaplan–meier analysis for overall survival in elderly patients (≥65 years) who underwent PSS and NPSS before PSM; (B) Kaplan–meier analysis for cancer-specific survival in elderly patients (≥65 years) who underwent PSS and NPSS before PSM; (C) Kaplan–meier analysis for overall survival in elderly patients (≥65 years) who underwent PSS and NPSS after PSM; (D) Kaplan–meier analysis for cancer-specific survival in elderly patients (≥65 years) who underwent PSS and NPSS after PSM.
Figure 2 Overall survival and cancer-specific survival in elderly patients (≥65 years) with metastatic pNET who underwent primary site surgery (PSS) and no primary site surgery (NPSS), before and after propensity score matching (PSM).

Figure 3 Kaplan–Meier analysis of cancer-specific survival for elderly patients (≥65 years) in sub-groups.

Notes: (A) Kaplan–meier analysis for cancer-specific survival in patients with age between 65 and 74 years and tumor of well or moderately differentiation; (B) Kaplan–meier analysis for cancer-specific survival in patients with age ≥75 years and tumor of well or moderately differentiation; (C) Kaplan–meier analysis for cancer-specific survival in patients with age between 65 and 74 years and tumor of poorly differentiation or undifferentiation; (D) Kaplan–meier analysis for cancer-specific survival in patients with age ≥75 years and tumor of poorly differentiation or undifferentiation.
Figure 3 Kaplan–Meier analysis of cancer-specific survival for elderly patients (≥65 years) in sub-groups.

Table S1 Multivariate regression analysis of characteristics for cancer-specific survival in patients with age 65–74 years+ well or moderately differentiated

Table S2 Multivariate regression analysis of characteristics for cancer-specific survival in patients with age ≥75 years+ well or moderately differentiated

Table S3 Multivariate regression analysis of characteristics for cancer-specific survival in patients with age 65–74 years+ poorly differentiated or undifferentiated

Table S4 Multivariate regression analysis of characteristics for cancer-specific survival in patients with age ≥75 years+ poorly differentiated or undifferentiated